Author:
Begna K,Abdelatif A,Schwager S,Hanson C,Pardanani A,Tefferi A
Publisher
Springer Science and Business Media LLC
Reference7 articles.
1. Brodsky I . Busulfan versus hydroxyurea in the treatment of polycythemia vera (PV) and essential thrombocythemia (ET). Am J Clin Oncol 1998; 21: 105–106.
2. Haanen C, Peetermans N, Cauchie C, Michel J, Strijckmans P, Mathe G et al. Treatment of polycythemia vera by radiophosphorous or busulphan: a randomized trial. "Leukemia and Hematosarcoma" Cooperative Group, European Organization for Research on Treatment of Cancer (E.O.R.T.C.). Br J Cancer 1981; 44: 75–80.
3. Berk PD, Goldberg JD, Donovan PB, Fruchtman SM, Berlin NI, Wasserman LR . Therapeutic recommendations in polycythemia vera based on Polycythemia Vera Study Group protocols. Semin Hematol 1986; 23: 132–143.
4. Hehlmann R, Heimpel H, Hasford J, Kolb HJ, Pralle H, Hossfeld DK et al. Randomized comparison of busulfan and hydroxyurea in chronic myelogenous leukemia: prolongation of survival by hydroxyurea. The German CML Study Group. Blood 1993; 82: 398–407.
5. Finazzi G, Caruso V, Marchioli R, Capnist G, Chisesi T, Cea F . Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study. Blood 2005; 105: 2664–2670.
Cited by
20 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献